promega and Hypertriglyceridemia

A multicentre, double blind, randomised between-group study comparing the triglyceride lowering effect of MaxEPA, a natural marine oil, and a placebo control is described. Eighty-six patients with hypertriglyceridaemia (fasting serum triglyceride greater than or equal to 2 mmol/l) were studied for three months. There were no significant differences between the groups (48 active, 38 control) in respect of age, sex, height or weight, smoking habits or alcohol consumption. After one month triglyceride levels were reduced significantly from baseline in the treatment group and there was also a highly significant difference between the groups in favour of the marine oil. There was no significant change in serum total cholesterol in either group but there were fluctuations in high density lipoprotein (HDL) in both groups. Minor gastrointestinal side effects were reported by patients in both groups. Standard haematological and biochemical tests were done and there were no significant changes from baseline.

Topics: Adolescent; Adult; Aged; Capsules; Cholesterol; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Fish Oils; Humans; Hypertriglyceridemia; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Time Factors; Triglycerides

Since it has been suggested that omega-3 polyunsaturated fatty acids (PUFA) may be an efficient treatment for dyslipoproteinaemia and renal function in uraemic patients, this study was carried out to evaluate the potential adverse effects of polyunsaturated acids on lipid peroxidation in patients with chronic renal failure.. Five uraemic predialysis patients with various renal diseases presenting progressive renal failure and moderate hypertriglyceridaemia (1.93 +/- 0.60 g/L) in comparison with the reference values of our laboratory (0.88 +/- 0.20 g/L) were given 6 g of fish oil per day for 6 months in the form of Maxepa capsules containing a low dose of tocopherol acetate (10.5 mg/day). During the treatment we investigated the effect (expected to be beneficial) of n-3 PUFA on triglyceride plasma levels and renal function. We also investigated the potential side effect of such a treatment on lipid peroxidation.. A moderate decrease of triglycerides early after the introduction of the treatment (1.93 +/- 0.6 g/L vs 1.33 +/- 0.58 g/L; 0 vs 0.5 months) was observed. In all patients, lipid peroxides measured as thiobarbituric acid reactants increased early after the introduction of the n-3 PUFA therapy (2.8 + 0.8 vs 3.76 +/- 0.15 mumol/L; 0 vs 0.5 months). Organic hyperoxides were significantly different in these patients compared with laboratory values, but they did not increase significantly during the treatment.. It must be noted that polyunsaturated fatty acids should be used with caution in predialysis patients.

Topics: Adult; Aged; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Hypertriglyceridemia; Lipid Peroxidation; Male; Middle Aged; Renal Dialysis; Thiobarbituric Acid Reactive Substances; Triglycerides; Uremia